-
Analysts See 100% Upside To Rigel After Tavalisse Approval
Wednesday, April 18, 2018 - 1:23pmRigel Pharmaceuticals, Inc. (NASDAQ: RIGL) announced Tuesday the approval of its Tavalisse for chronic immune thrombocytopenia — an achievement prompting a 14-percent pop in its stock price. Analysts echoed investor enthusiasm, with H.C. Wainwright increasing its price target from $6.70 to $8...
Read More >> -
HC Wainwright: Why The Upside Potential For Palatin Technologies Is Nearly Fivefold
Friday, April 6, 2018 - 2:43pmPalatin Technologies, Inc. (NYSE: PTN), a biopharmaceutical company that focuses on treatments for diseases with significant unmet medical needs, boasts a lead asset, bremelanotide, that has an "arousing number of major boxes checked," according to H.C. Wainwright. The Analyst H.C....
Read More >> -
What's NeuVax? Wainwright Says Sellas' Cancer Vaccine Candidate Makes It A Buy
Monday, April 2, 2018 - 12:18pmSellas Life Sciences Group Inc (NASDAQ: SLS) popped as much as 189 percent Monday after reporting “clinically meaningful activity” in interim data for its Phase 2b NeuVax trial. H.C. Wainwright liked the stock before it peaked, though, and it considers NeuVax just a footnote in the...
Read More >> -
HC Wainwright Takes Bullish Stance On Two Cancer-Focused Pharma Companies
Thursday, March 8, 2018 - 4:23pmAnalysts at H.C. Wainwright initiated coverage Thursday on two pharmaceutical companies developing cancer-related vaccines and treatments. Interpace: Efficient Diagnosis, Expanding Reimbursement Coverage Analyst Raghuram Selvaraju initiated coverage on Interpace Diagnostics Group, Inc. (NASDAQ:...
Read More >> -
This Strata Skin Analyst Is Modeling For More Than 400% Upside In Stock
Wednesday, October 18, 2017 - 8:55amStrata Skin Sciences, Inc. (NASDAQ: SSKN), a nano-cap medical technology company that develops, commercializes and markets innovative products for the treatment of dermatologic conditions, has a more than 400 percent upside, according to HC Wainwright & Co's Joseph Pantginis. Pantginis...
Read More >> -
Analyst Sees Near-Term Inflection Point For Aptose Biosciences, Upgrades Stock
Thursday, September 7, 2017 - 9:23amAptose Biosciences Inc (NASDAQ: APTO) is seeing a strong run in pre-market trading Thursday following H.C. Wainwright & Co's upgrade. The firm premised its opinion change on its belief that an inflection point may be drawing near. As such, the firm upgraded shares of Aptose from Neutral to...
Read More >> -
Analyst Makes The Case For Ligand As A 'Core' Holding
Tuesday, September 5, 2017 - 8:49amAnalysts at H.C. Wainwright & Co. continue to see Ligand Pharmaceuticals Inc. (NASDAQ: LGND) as a "core long term holding" for investors. The firm's Joseph Pantginis initiated coverage of the biopharmaceutical company with a Buy rating and $150 price target, mostly due to the company's business...
Read More >> -
Cytokinetics Still A Buy After Phase 2 SMA Data
Thursday, March 23, 2017 - 8:46amData presented by Cytokinetics, Inc. (NASDAQ: CYTK) showed CK-107 has the ability to positively impact two different animal models of spinal muscular atrophy. Rodman & Renshaw’s Joseph Pantginis reiterated a Buy rating on the company, with a price target of $25. Positive Indications The...
Read More >> -
Aptose Upgraded To Buy At Roth, Price Target Doubled
Monday, June 13, 2016 - 8:58amRoth Capital has upgraded Aptose Biosciences Inc (NASDAQ: APTO) to Buy from Neutral "on an expected inflection point in the near-term, namely the allowance for APTO-253 to return to the clinical." Belonging to a new small molecules class, APTO-253 "is designed to induce a silent tumor-suppressive...
Read More >> -
Roth Resumes Coverage On Fibrocell With Buy Rating, $7 Target
Tuesday, May 24, 2016 - 9:28amFibrocell Science Inc (NASDAQ: FCSC) is leveraging its expertise with fibroblasts to target monogenic diseases as well as broader indications. Roth Capital Partners’ Joseph Pantginis resumed coverage of the company with a Buy rating and a $7 price target. Fibrocell plans using gene...
Read More >>